Skip to main content

12-09-2022 | ESMO 2022 | Conference coverage | Video

IMvigor130 analysis highlights need to standardize PD-L1 expression assessment

share
SHARE

Enrique Grande Pulido takes us through an exploratory analysis of the IMvigor130 trial of atezolizumab in metastatic urothelial cancer focusing on the differences in outcomes according to the assay used to assess PD-L1 expression, and highlights the clinical relevance of the findings (5:14).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany